已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Transarterial chemoembolization combined with lenvatinib and camrelizumab for unresectable hepatocellular carcinoma: A prospective, single-arm, multicenter study.

医学 伦瓦提尼 肝细胞癌 内科学 临床终点 不利影响 外科 肿瘤科 索拉非尼 临床试验
作者
Zhibo Zhang,Mao-Lin Yan,Yufeng Chen,Xukun Wu,Lan-Fang Yang,Zhengyu Yin,Hao Liu,Yongyi Zeng,Hui Zhang,Jinke Huang,Jiafei Chen,Liang Wang,Zhongwu Chen
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:41 (16_suppl): 4072-4072
标识
DOI:10.1200/jco.2023.41.16_suppl.4072
摘要

4072 Background: Conversion therapy for unresectable hepatocellular carcinoma (uHCC) has attracted increasing interest in recent years. In 2020 ASCO annual meeting, one abstract reported that the combination therapy of tyrosine kinase inhibitor and anti-PD-1 antibody could be a promising conversion therapy for patients with initially uHCC. This study aims to evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with lenvatinib and camrelizumab (TACE+LEN+CAM) as a conversion therapy for uHCC. Methods: This single-arm, prospective, multicenter study was conducted on patients diagnosed with HCC (with an Eastern Cooperative Oncology Group performance score (ECOG PS) of 0-1 and Child-Pugh class A) who were ineligible for surgery. Enrolled patients received camrelizumab (200 mg every 3 weeks) and lenvatinib (bodyweight ≥ 60 kg: 12 mg/day; < 60 kg: 8 mg/day) after TACE treatment. Surgery was performed after treatment response was assessed to meet the criteria of resection. Patients who did not meet the criteria for surgery continued to receive triple treatment until disease progression or intolerable toxicity. Primary endpoints were objective response rate (ORR)and safety. Secondary endpoints included percentage of patients amendable to surgery, the rate of radical (R0) resection, disease control rate (DCR). This study is registered with Chinese Clinical Trial Registry (ChiCTR2100050410). Results: Between Oct 25, 2021, and Jul 20, 2022, 55 patients were enrolled and received triple therapy (TACE+LEN+CAM). Of these, 37 (67.3%) patients had portal vein tumor thrombosis. Mean tumor diameter for all patients was 112 ± 83 mm. 52 (94.6%) patients with≤2 target lesions, and 3 (5.4%) patients with > 2 target lesions. As of data cutoff on Dec 20, 2022, the median follow-up was 6.7 months (IQR 5.0-9.89). According to modified RECIST criteria, tumor response in patients included complete response to treatment in 9 patients (18.0%), partial response in 27 (54.0%), stable disease in 6 (12.0%), and progressive disease in 7 (14.0%). The ORR was 72.0%, and the DCR was 84.0%. 26 patients underwent surgery after successful conversion therapy. The MPR and pCR rates in the surgery population were 69.2% and 23.1%, respectively. The conversion rate was 55.3% and the R0 resection rate was 100%. 23 (41.8%) of 55 patients had treatment-related adverse event (TRAEs) that were grade 3-5. No grade 3-5 TRAEs occurred after surgery. Conclusions: The triple therapy (TACE+LEN+CAM) significantly improved ORR and the surgical conversion rate of uHCC patients with a manageable safety. Future large-scale randomised trials are warranted. Clinical trial information: ChiCTR2100050410 .

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
背后煎蛋完成签到 ,获得积分10
刚刚
1秒前
愤怒的雪巧完成签到,获得积分10
1秒前
丘比特的应助被陶1122采纳,获得10
3秒前
3秒前
十三州府发布了新的文献求助10
3秒前
4秒前
吃个橘子吧完成签到,获得积分10
4秒前
充电宝的应助被silhouette采纳,获得10
5秒前
章鱼哥完成签到 ,获得积分10
5秒前
Akim的应助被BAEKHYUNLUCKY采纳,获得10
7秒前
stella发布了新的文献求助10
7秒前
FashionBoy的应助被Tngannnnnn0910采纳,获得10
10秒前
10秒前
Abandon1完成签到 ,获得积分10
10秒前
11秒前
十三州府完成签到,获得积分10
12秒前
wzr完成签到 ,获得积分10
13秒前
今后的应助被020306采纳,获得10
15秒前
cc发布了新的文献求助10
16秒前
努力不延毕的土豆焖鸡完成签到,获得积分10
16秒前
Vincent完成签到,获得积分10
16秒前
17秒前
17秒前
HB完成签到,获得积分10
17秒前
18秒前
Maestro_S的应助被科研通管家采纳,获得10
19秒前
852的应助被科研通管家采纳,获得10
19秒前
斯文败类的应助被科研通管家采纳,获得10
19秒前
19秒前
19秒前
再见不难完成签到,获得积分10
19秒前
20秒前
思源的应助被香蕉静芙采纳,获得10
21秒前
翻翻发布了新的文献求助10
21秒前
月见完成签到 ,获得积分10
21秒前
雪糕完成签到,获得积分10
22秒前
小燕尾条发布了新的文献求助10
22秒前
充电宝的应助被朱湋帆采纳,获得10
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8172481
求助须知:如何正确求助?哪些是违规求助? 9565240
关于积分的说明 21778496
捐赠科研通 7764217
什么是DOI,文献DOI怎么找? 3431362
关于科研通互助平台的介绍 2555275
邀请新用户注册赠送积分活动 2476362